title: Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
authors.affiliation: St. Jude Children's Research Hospital and University of Tennessee College of Medicine, Memphis, Tennessee 38105-2794, USA. sheri.spunt@stjude.org
authors.forename: Sheri L
authors.initials: SL
authors.lastname: Spunt
authors.forename: Lynette M
authors.initials: LM
authors.lastname: Smith
authors.forename: Frederick B
authors.initials: FB
authors.lastname: Ruymann
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Qualman
authors.forename: Sarah S
authors.initials: SS
authors.lastname: Donaldson
authors.forename: David A
authors.initials: DA
authors.lastname: Rodeberg
authors.forename: James R
authors.initials: JR
authors.lastname: Anderson
authors.forename: William M
authors.initials: WM
authors.lastname: Crist
authors.forename: Michael P
authors.initials: MP
authors.lastname: Link
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000494:pharmacology*; D018572:Disease-Free Survival; D004317:Doxorubicin; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D020714:Maximum Tolerated Dose; D012208:Rhabdomyosarcoma / Q000188:drug therapy*; D012306:Risk; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide